

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

MAVER-1

RRID:CVCL_1831

Type: Cell Line

Proper Citation

RRID:CVCL_1831

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1831

Proper Citation: RRID:CVCL_1831

Description: Cell line MAVER-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Mantle cell lymphoma

Defining Citation: [PMID:16434369](#), [PMID:24362935](#), [PMID:25315077](#), [PMID:25688540](#), [PMID:25960936](#), [PMID:27697772](#), [PMID:29666304](#)

Comments: Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank)., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MAVER-1

Synonyms: Maver-1, MAVER1, Maver1, MAVER, MAntle cell VERona-1

Cross References: ATCC:CRL-3008, BioSample:SAMN03471709, cancercellines:CVCL_1831, ChEMBL-Cells:ChEMBL4482995, ChEMBL-Targets:ChEMBL4483260, Cosmic:2078182, Cosmic:2088018, DepMap:ACH-002485, DSMZ:ACC-717, DSMZCellDive:ACC-717, GEO:GSM1044978, GEO:GSM1044979, GEO:GSM1044980, GEO:GSM1044981, GEO:GSM1266781, GEO:GSM1266782, GEO:GSM1266793, GEO:GSM1266794, GEO:GSM1266795, GEO:GSM1266796, GEO:GSM1266797, GEO:GSM1266798, GEO:GSM2322621, IARC_TP53:24552, PubChem_Cell_line:CVCL_1831, Wikidata:Q54904067

ID: CVCL_1831

Record Creation Time: 20220427T220747+0000

Record Last Update: 20260905T181108+0000

Ratings and Alerts

No rating or validation information has been found for MAVER-1.

No alerts have been found for MAVER-1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Demel UM, et al. (2026) Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(17), e11449.

Reversat A, et al. (2025) Mass Cytometry-Based Approach for the Investigation of Stimulator of Interferon Genes Pathway. European journal of immunology, 55(12), e70101.

Yang C, et al. (2025) A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity. Cell reports. Medicine, 6(10), 102409.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. Cell, 188(2), 331.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Nicosia L, et al. (2023) Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. Cancer cell, 41(12), 2136.

Roider T, et al. (2021) The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. International journal of cancer, 148(1), 150.

Portelinha A, et al. (2021) ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. Cell reports. Medicine, 2(7), 100350.

Shemorry A, et al. (2019) Caspase-mediated cleavage of IRE1 controls apoptotic cell commitment during endoplasmic reticulum stress. *eLife*, 8.